Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
PMID: 25900608
Involving over 13,000 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, this trial demonstrated that tirzepatide was non-inferior to dulaglutide for three-point major adverse cardiovascular events (MACE)
Clinical trials show it can help patients lose an average of around 14.9% of body weight when combined with lifestyle changes
Vitamin A provides a wide range of nutritional
Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord
Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
US$ 20.05
US$ 28.02
US$ 22.80
US$ 25.64
US$ 28.55
